ORPHA:300869
Splenic diffuse red pulp small B-cell lymphoma
Also known as: SDRPL · Splenic diffuse red pulp lymphoma
Publications
199
75.2th percentile
Trials
0
Interventional, condition-specific
Researchers
1,225
Distinct authors in sample
Gene link
—
Readiness
1/6
Stages with a signal
Clinical definition (Orphanet)
Splenic diffuse red pulp small B-cell lymphoma is a rare, indolent B-cell non-Hodgkin lymphoma characterized by abnormal proliferation of small, monomorphous, basophilic B-lymphocytes, with villous cytoplasm, in the splenic red pulp, bone marrow and peripheral blood. It typically presents in the late clinical stages with and moderate lymphocytosis. Cytopenias are rare and likely associated with hypersplenism.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0017599
- UMLS:C2699508
- NCIT:C80309
Additional Mondo synonyms (1)
splenic diffuse red pulp lymphoma
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
1/6 stages with a signal
Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
199 matched papers (161 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
199
199 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
199 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
161 in the last 10 years · high confidence · 75.2th percentile (publications denominator)
Phrase hits: 199 · MeSH hits: 0
Who's working on it?
1,225
Distinct author names in 199 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Troussard X20 papers · 2025
Department of Hematology, Centre Hospitalier Universitaire Côte de Nacre, Caen, France.
Papers in Europe PMC - 02Traverse-Glehen A12 papers · 2022
INSERM 1052, CNRS 5286, Université Claude Bernard, Faculté de Médecine Lyon-Sud Charles Mérieux, Université de Lyon, 69495 Pierre Bénite, France. alexandra.traverse-glehen@chu-lyon.fr.
Papers in Europe PMC - 03Baseggio L11 papers · 2023
Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Laboratoire d'hématologie, 69495 Pierre Bénite, France. lucile.baseggio@chu-lyon.fr.
Papers in Europe PMC - 04Jaffe ES11 papers · 2023
Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA. elainejaffe@nih.gov
Papers in Europe PMC - 05Maitre E11 papers · 2025
Normandie Univ, INSERM U1245, Université de Caen, Caen, France.
Papers in Europe PMC - 06Salles G11 papers · 2024
Hospices Civils de Lyon/Université de Lyon, Pierre-Bénite, France.
Papers in Europe PMC - 07Campo E9 papers · 2024
Hematopathology Section, Department of Anatomic Pathology, Hospital Clinic, Institute of Biomedical Research August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain. elainejaffe@nih.gov
Papers in Europe PMC - 08Cornet E9 papers · 2022
Laboratoire d'Hematologie Biologique, CHU de Caen, Caen, France.
Papers in Europe PMC - 09Paillassa J7 papers · 2025
Service des Maladies du Sang, CHU d'Angers, Angers, France.
Papers in Europe PMC - 10Wotherspoon A7 papers · 2024
Department of Histopathology, Royal Marsden Hopsital, Fulham Road, London SW3 6JJ, UK. Electronic address: Andrew.Wotherspoon@rmh.nhs.uk.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Splenic diffuse red pulp small B-cell lymphoma" OR "SDRPL" OR "Splenic diffuse red pulp lymphoma"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Splenic diffuse red pulp small B-cell lymphoma" OR "SDRPL" OR "Splenic diffuse red pulp lymphoma"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T12:44:53.505Z